ANTI-TNFα ANTIBODY INDUCED PSORIASIFORM SKIN LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE; AN IRISH COHORT STUDY.

Related Articles

ANTI-TNFα ANTIBODY INDUCED PSORIASIFORM SKIN LESIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE; AN IRISH COHORT STUDY.

QJM. 2017 Jan 09;:

Authors: Kirthi S, Tobin AM, Hussey M, Scaldaferri F, McNamara D

Abstract
AIM: To determine the prevalence of psoriasis in an IBD cohort with reference to clinical characteristics and anti-TNFα use.
METHODS: Patients with psoriasis and IBD were retrospectively identified from the IBD database at Tallaght Hospital from 2000 to 2015. Pertinent clinical data were obtained from patients notes including anti-TNFα exposure. Prevalence rates of genuine and reactive psoriasis were calculated and compared using a students T-test. A p value of < 0.05 was considered significant.
RESULTS: In total, 1384 IBD patients were identified. The overall prevalence rate of IBD and psoriasis was 2.4% (n = 33), with 1.8% (n = 25) in the Crohn's Disease (CD) group and 0.6% (n = 8) in the Ulcerative Colitis (UC) group. Within the psoriasis group, 24% (n = 8 of 33) had reactive psoriasis. The prevalence rate of psoriasis in the non-biologic and biologic cohort were similar 2.5% (25 of 981) and 2% (8 of 403) respectively. There was no significant association with reactive psoriasis and disease type. There was a trend towards higher rates of reactive psoriasis Adalimumab users, 3.6% (6 of 166) vs. 0.8% (2 of 237), OR = 4.283, p = 0.077, 95% CI 0.854 to 21.483 in Infliximab users. In addition, in our cohort, smoking was not associated with any form of psoriasis in IBD, OR = 1.377, 95% CI 0.061-3.087, p = 0.437.
CONCLUSION: In our large study, the prevalence rate of reactive psoriasis was similar to the background rate of psoriasis in the overall IBD cohort (2.0% vs 2.4%). A 2% prevalence rate represents a common adverse event that clinicians should be aware of.

PMID: 28069913 [PubMed - as supplied by publisher]

http://ift.tt/2ifpaHY